TABLE 2.

TAF antiviral activities against HIV primary isolates

HIV type	Isolate group	Isolate subtype	Isolate	EC50 (nM)a
				TAF	AZT
HIV-1	M	A	92UG029	8.75	26.4
			92UG037	0.69	2.12
			92RW016	0.71	1.53
		B	93BR021	9.69	48.0
			JR-CSF	1.05	1.95
			90US873	3.87	6.03
		C	92BR025	4.16	9.00
			98BR004	1.75	7.56
			93IN101	1.50	5.49
		D	92UG001	3.79	11.3
			92UG046	0.99	3.33
			92UG024	6.27	7.21
		E	93TH073	1.18	3.54
			CMU06	1.36	4.09
			CMU08	5.88	13.1
		F	93BR019	0.73	4.87
			92BR024	5.97	17.1
			93BR029	0.14	1.28
			93BR020	2.22	7.41
		G	G3	5.34	14.0
			RU570	12.0	66.4
			JV1083	9.85	27.4
	N	NAb	YBF30	1.98	5.23
	O	NA	BCF02	1.30	1.23
			BCF03	3.01	7.20
			BCF07	0.10	3.81
HIV-2	NA	NA	CDC310319	2.63	15.6
			CDC310342	1.96	1.39
			CBL-20	0.91	2.18

^aThe mean TAF EC₅₀ values for each subtype/group were as follows: A, 3.4 nM; B, 4.9 nM; C, 2.5 nM; D, 3.7 nM; E, 2.8 nM; F, 2.3 nM; G, 9.1 nM; N, not applicable; O, 1.5 nM; HIV-2, 1.8 nM.

^bNA, not applicable.